Palatin Technologies Swings to Profit on Licensing Deal, Bolsters Cash

TL;DR

**PTN just pulled off a massive financial pivot with a licensing deal and fresh capital, making it a speculative buy for the next 12 months.**

AI Summary

PALATIN TECHNOLOGIES INC reported a significant financial turnaround for the three months ended September 30, 2025, achieving a net income of $4,677,534, a stark contrast to the net loss of $7,823,649 in the prior year period. This positive shift was primarily driven by $8,847,550 in collaboration and license revenue, compared to zero in the same period last year. Operating expenses decreased substantially, with research and development falling from $5,743,754 to $2,525,766, and selling, general and administrative expenses decreasing from $2,020,931 to $1,660,731. The company's cash and cash equivalents stood at $1,273,083 as of September 30, 2025, down from $2,564,265 at June 30, 2025, but subsequent funding events, including $5,400,000 from Boehringer Ingelheim and $16,900,000 from a public offering in October and November 2025, have significantly bolstered its liquidity. The company also executed a 1-for-50 reverse stock split on August 11, 2025, and its common stock was reinstated on the NYSE American on November 12, 2025, after a temporary delisting. Despite a historical accumulated deficit of $454,396,365, management now believes it has sufficient funds to operate for the next twelve months.

Why It Matters

This 10-Q signals a critical turning point for Palatin Technologies, moving from significant losses to profitability, largely due to the Boehringer Ingelheim licensing deal. For investors, the substantial cash infusion of over $22 million post-quarter-end, coupled with the NYSE American relisting, significantly de-risks the company's near-term liquidity concerns and enhances its market visibility. This could attract new institutional interest and potentially stabilize its volatile stock price, which had been delisted. Competitively, this financial strengthening allows Palatin to advance its melanocortin receptor pipeline, potentially challenging rivals in obesity, dry eye disease, and inflammatory conditions, while the Vyleesi sale to Cosette Pharmaceuticals provides ongoing milestone potential.

Risk Assessment

Risk Level: medium — While Palatin Technologies has significantly improved its liquidity with recent funding, the company still carries an accumulated deficit of $454,396,365 as of September 30, 2025, indicating a long history of unprofitability. Its future profitability remains dependent on successful clinical trials and regulatory approvals for its pipeline products, which are inherently uncertain and costly, as highlighted by the anticipated significant future expenses for development programs.

Analyst Insight

Investors should closely monitor Palatin's progress in its clinical trials, particularly for its MC4R obesity programs and PL9643 for dry eye disease, as these represent the primary drivers for sustained future revenue. Given the recent capital raise and NYSE American relisting, consider this a speculative investment with potential upside if pipeline milestones are met, but be aware of the long-term development risks inherent in biopharmaceuticals.

Financial Highlights

debt To Equity

N/A

revenue

$8,847,550

operating Margin

52.5%

total Assets

$8,614,660

total Debt

$8,218,261

net Income

$4,677,534

eps

$4.81

gross Margin

N/A

cash Position

$1,273,083

revenue Growth

N/A

Revenue Breakdown

Key Numbers

• $4.68M — Net Income (Swung from a $7.82M loss in Q3 2024 to a $4.68M profit in Q3 2025, driven by collaboration revenue.)
• $8.85M — Collaboration and License Revenue (Generated $8.85M in Q3 2025, up from $0 in Q3 2024, a key driver of profitability.)
• $1.27M — Cash and Cash Equivalents (As of September 30, 2025, but significantly bolstered by $22.3M in post-quarter funding.)
• $2.53M — Research and Development Expenses (Decreased by 56% from $5.74M in Q3 2024 to $2.53M in Q3 2025.)
• $454.40M — Accumulated Deficit (Reduced from $459.07M at June 30, 2025, but still represents significant historical losses.)
• 1-for-50 — Reverse Stock Split (Effective August 11, 2025, impacting share count and per-share metrics.)
• 1,702,675 — Common Shares Outstanding (As of November 12, 2025, post-reverse split and public offering.)
• $4.81 — Basic Net Income Per Common Share (A significant improvement from a basic net loss of $(19.71) per share in Q3 2024.)

Key Players & Entities

• PALATIN TECHNOLOGIES INC (company) — registrant
• Boehringer Ingelheim International GmbH (company) — acquired Palatin intellectual property
• Cosette Pharmaceuticals, Inc. (company) — acquired Vyleesi product
• NYSE American LLC (regulator) — stock exchange for PTN
• $4,677,534 (dollar_amount) — Net income for the three months ended September 30, 2025
• $8,847,550 (dollar_amount) — Collaboration and license revenue for the three months ended September 30, 2025
• $1,273,083 (dollar_amount) — Cash and cash equivalents as of September 30, 2025
• $5,400,000 (dollar_amount) — Cash received from Boehringer Ingelheim in October 2025
• $16,900,000 (dollar_amount) — Net proceeds from public offering closed November 12, 2025
• $454,396,365 (dollar_amount) — Accumulated deficit as of September 30, 2025

FAQ

Risk Factors

• Going Concern and Liquidity [high — financial]: The company historically had substantial accumulated deficits. While recent funding events in October and November 2025 totaling $22.3 million have bolstered liquidity and removed prior substantial doubt about the ability to continue as a going concern, future funding needs and operational execution remain critical.
• Dependence on Key Partnerships [high — operational]: The company's revenue and accounts receivable are generated by one customer, indicating a significant concentration risk. The success of future development and commercialization efforts heavily relies on the performance and continuation of these key partnerships.
• Product Development and Regulatory Approval [high — regulatory]: As a biopharmaceutical company, Palatin's success is contingent on the successful development and FDA approval of its product candidates. Delays or failures in clinical trials or regulatory submissions can significantly impact financial performance and future prospects.
• Historical Accumulated Deficit [medium — financial]: The company has a significant accumulated deficit of $454,396,365 as of September 30, 2025. While recent revenue and funding have improved the financial position, this historical loss underscores the capital-intensive nature of drug development and the need for sustained profitability.
• Reliance on Research and Development [medium — operational]: The company's core business relies on ongoing research and development activities. While R&D expenses decreased to $2,525,766 in Q3 2025 from $5,743,754 in Q3 2024, continued investment is necessary for pipeline advancement, and any disruption could impact future revenue streams.
• Competition in Therapeutic Areas [medium — market]: Palatin operates in competitive therapeutic areas such as obesity, metabolic disorders, and inflammatory diseases. The presence of established players and emerging biotechs necessitates continuous innovation and differentiation to capture market share.

Industry Context

Palatin Technologies operates in the biopharmaceutical sector, focusing on developing first-in-class medicines targeting the melanocortin receptor system. This highly competitive industry requires significant R&D investment and faces long development timelines and stringent regulatory hurdles. Key areas of focus include obesity, metabolic disorders, and inflammatory diseases, where unmet medical needs present significant market opportunities.

Regulatory Implications

As a biopharmaceutical company, Palatin is subject to extensive regulation by bodies like the FDA. Successful development and commercialization depend on navigating complex clinical trial processes and obtaining regulatory approvals. Any delays or failures in these processes pose significant risks. Furthermore, compliance with financial reporting standards (U.S. GAAP) and exchange listing requirements is crucial for maintaining investor confidence and market access.

What Investors Should Do

1. Monitor R&D Pipeline Progress
2. Assess Partnership Sustainability
3. Evaluate Cash Burn and Future Funding Needs
4. Observe Market Reinstatement and Stock Performance

Key Dates

• 2025-08-11: Reverse Stock Split — Executed a 1-for-50 reverse stock split, impacting share count and per-share metrics, which is often done to meet exchange listing requirements or improve stock price perception.
• 2025-10-01: Boehringer Ingelheim Funding — Received $5,400,000 in cash, significantly improving liquidity and demonstrating partnership validation.
• 2025-11-12: Public Offering Closes — Closed a public offering, raising approximately $16,900,000 in net proceeds, further strengthening the company's financial position and removing going concern doubts.
• 2025-11-12: NYSE American Reinstatement — Common stock reinstated on the NYSE American after a temporary delisting, providing improved market access and investor confidence.
• 2025-09-30: Quarter End — End of the fiscal third quarter, with reported net income of $4,677,534 and cash balance of $1,273,083.
• 2024-09-30: Prior Year Quarter End — End of the prior year's third quarter, during which the company reported a net loss of $7,823,649.

Glossary

Melanocortin Receptor System

A system of receptors in the body that influences various physiological processes including metabolism, inflammation, and immune responses. Palatin is developing drugs that modulate this system. (This is the core scientific basis for Palatin's drug development pipeline, particularly for obesity and inflammatory diseases.)

MC4R agonists

Molecules that activate the Melanocortin 4 Receptor, which plays a role in regulating food intake and metabolism. Palatin is developing these for obesity treatment. (Represents a key product candidate area for the company.)

Accumulated Deficit

The total net losses a company has incurred since its inception, minus any net gains. It represents a negative balance in retained earnings. (Indicates the company's historical unprofitability, though recent performance shows a positive trend.)

Reverse Stock Split

A corporate action where a company reduces the number of its outstanding shares by consolidating them, typically to increase the share price. (Affects share count and per-share metrics, and was implemented on August 11, 2025.)

Going Concern

An accounting assumption that a company will continue to operate for the foreseeable future. If substantial doubt exists, it must be disclosed. (Management believes recent funding has removed substantial doubt about Palatin's ability to continue as a going concern.)

Collaboration and License Revenue

Revenue generated from agreements with other companies for the right to use intellectual property or to collaborate on development projects. (This was the primary driver of Palatin's significant net income in the current quarter.)

Year-Over-Year Comparison

Compared to the prior year period ended September 30, 2024, Palatin Technologies has experienced a dramatic financial turnaround. Revenue has shifted from $0 to $8,847,550 due to collaboration and license agreements. This revenue surge, coupled with a significant reduction in operating expenses (R&D down 56% to $2,525,766, SG&A down 17.8% to $1,660,731), has resulted in a net income of $4,677,534, a stark contrast to the net loss of $7,823,649 in the prior year. While cash reserves decreased sequentially from June 30, 2025, substantial post-quarter funding has significantly improved liquidity, mitigating prior going concern risks.

Key Financial Figures

• $0.01 — ch Registered Common Stock, par value $0.01 per share PTN1 NYSE American Indic
• $1,273,083 — quivalents as of September 30, 2025, of $1,273,083 and approximately $ 5,400,000 in cash r

Filing Documents

• ptn_10q.htm (10-Q) — 681KB
• ptn_ex103.htm (EX-10.3) — 404KB
• ptn_ex311.htm (EX-31.1) — 13KB
• ptn_ex312.htm (EX-31.2) — 14KB
• ptn_ex321.htm (EX-32.1) — 2KB
• ptn_ex322.htm (EX-32.2) — 2KB
• ptn_10qimg27.jpg (GRAPHIC) — 33KB
• ptn_10qimg28.jpg (GRAPHIC) — 53KB
• ptn_10qimg20.jpg (GRAPHIC) — 5KB
• 0001654954-25-013091.txt ( ) — 4462KB
• ptn-20250930.xsd (EX-101.SCH) — 52KB
• ptn-20250930_lab.xml (EX-101.LAB) — 252KB
• ptn-20250930_cal.xml (EX-101.CAL) — 35KB
• ptn-20250930_pre.xml (EX-101.PRE) — 193KB
• ptn-20250930_def.xml (EX-101.DEF) — 88KB
• ptn_10q_htm.xml (XML) — 524KB

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION Item 1.

Financial Statements (Unaudited)

Financial Statements (Unaudited) 5 Consolidated Balance Sheets as of September 30, 2025 and June 30, 2024 5 Consolidated Statements of Operations for the Three Months Ended September 30, 2025 and 2024 6 Consolidated Statements of Changes in Stockholders' Equity (Deficiency) for the Three Months Ended September 30, 2025 and 2024 7 Consolidated Statements of Cash Flows for the Three Months Ended September 30, 2025 and 2024 8

Notes to Consolidated Financial Statements

Notes to Consolidated Financial Statements 9 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 22 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 25 Item 4.

Controls and Procedures

Controls and Procedures 25

– OTHER INFORMATION

PART II – OTHER INFORMATION

Legal Proceedings

Legal Proceedings 26 Item 1A.

Risk Factors

Risk Factors 26 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 26 Item 3. Defaults Upon Senior Securities 26 Item 4. Mine Safety Disclosures 26 Item 5. Other Information 26 Item 6. Exhibits 27

Signatures

Signatures 28 2 Table of Contents Special Note Regarding Forward-Looking Statements In this Quarterly Report on Form 10-Q (this "Quarterly Report") references to "we," "our," "us," the "Company" or "Palatin" mean Palatin Technologies, Inc. and its subsidiary. our ability to obtain additional financing on terms acceptable to us, or at all, including unavailability of funds or delays in receiving funds as a result of economic disruptions; our expectation that we will incur losses for the foreseeable future and may never achieve or maintain profitability; our business, financial condition, and results of operations may be adversely affected by increases in costs of and delays in conducting human clinical trials and the performance of our contractors and suppliers, reduction in our productivity or the productivity of our contractors and suppliers, supply chain constraints, and labor shortages; whether Boehringer Ingelheim International GmbH ("Boehringer Ingelheim"), which in August 2025 acquired certain Palatin intellectual property to first-in-class melanocortin receptor-targeted peptides developed by Palatin, will be able to successfully develop a product for the treatment of retinal diseases, including diabetic retinopathy; whether Cosette Pharmaceuticals, Inc. ("Cosette"), which acquired our Vy

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements. PALATIN TECHNOLOGIES, INC . and Subsidiary Consolidated Balance Sheets (unaudited) September 30, 2025 June 30, 2025 ASSETS Current assets: Cash and cash equivalents $ 1,273,083 $ 2,564,265 Accounts Receivable 6,886,441 - Other receivables 19,786 29,468 Prepaid expenses and other current assets 190,468 325,695 Total current assets 8,369,778 2,919,428 Property and equipment, net 115,057 129,444 Right-of-use assets - operating leases 129,825 161,166 Other assets - 56,916 Total assets $ 8,614,660 $ 3,266,954 LIABILITIES AND STOCKHOLDERS' DEFICIENCY Current liabilities: Accounts payable $ 7,405,849 $ 6,998,806 Accrued expenses 679,966 881,412 Short-term operating lease liabilities 132,446 129,812 Total current liabilities 8,218,261 8,010,030 Long-term operating lease liabilities - 33,969 Total liabilities 8,218,261 8,043,999 Commitments and contingencies (Note 10) Stockholders' deficiency: Preferred stock of $ 0.01 par value – authorized 10,000,000 shares: shares issued and outstanding designated as follows: Series A Convertible: authorized 4,030 shares as of September 30, 2025: issued and outstanding 4,030 shares as of September 30, 2025 and June 30, 2025 40 40 Series D Convertible: authorized 3,400 shares as of September 30, 2025: issued and outstanding 3,400 shares as of September 30, 2025 and June 30, 2025 34 34 Common stock of $ 0.01 par value – authorized 300,000,000 shares: issued and outstanding 973,291 shares as of September 30, 2025 and 929,597 shares as of June 30, 2025 9,734 9,296 Additional paid-in capital 454,782,956 454,287,484 Accumulated deficit ( 454,396,365 ) ( 459,073,899 ) Total stockholders' equity (deficiency) 396,399 ( 4,777,045 ) Total liabilities and stockholders' deficiency $ 8,614,660 $ 3,266,954 The accompanying notes are an integral part of these consolidated financial statements.

Notes to Consolidated Financial Statements

Notes to Consolidated Financial Statements (1) ORGANIZATION Nature of Business - Palatin Technologies, Inc. ("Palatin" or the "Company") is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor ("MCR") system. The Company's product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Melanocortin Receptor System. The MCR system has effects on food intake, metabolism, sexual function, inflammation, and immune system responses. There are five melanocortin receptors, MC1R through MC5R. Modulation of these receptors, through use of receptor-specific agonists, which activate receptor function, or receptor-specific antagonists, which block receptor function, can have significant pharmacological effects. The Company's product development activities focus primarily on use of MC4R agonists for treatment of obesity. The Company is developing MC4R peptides and small molecule agonists with potential utility in obesity and metabolic-related disorders, rare MC4R pathway diseases, such as hypothalamic obesity, and orphan indications. The Company is also developing, dependent on resources for development activities, MC1R agonist products, with potential to treat inflammatory and autoimmune diseases, such as dry eye disease, which is also known as keratoconjunctivitis sicca, uveitis, diabetic retinopathy, and inflammatory bowel disease. The Company believes that the MC1R agonist peptides in development have broad anti-inflammatory effects and appear to utilize mechanisms engaged by the endogenous melanocortin system in regulation of the immune system and resolution of inflammatory responses. The Company is also developing, dependent on resources for development activities, peptides and small molecules that are active at more than one melanocortin receptor, with potential utility in obesity and metab

Notes to Consolidated Financial Statements

Notes to Consolidated Financial Statements Based on the Company's available cash and cash equivalents as of September 30, 2025, of $1,273,083 and approximately $ 5,400,000 in cash received during October 2025 in conjunction with the agreement with Boehringer Ingelheim, and approximately $ 16,900,000 in net proceeds from a public offering which closed on November 12, 2025, management has concluded that the prior conditions and events raising substantial doubt about the Company's ability to continue as a going concern no longer exist as of the date these financial statements are issued. Based on the company's operating and development plan, The Company expects that its existing cash and cash equivalents as of the date of this filing will be sufficient to enable it to fund operations through the next twelve months following the issuance of the financial statements. Concentrations – Concentrations in the Company's assets and operations subject it to certain related risks. Financial instruments that subject the Company to concentrations of credit risk primarily consist of cash, cash equivalents, and accounts receivable. The Company's cash and cash equivalents are primarily invested in one investment account sponsored by a large financial institution. The Company's revenue and accounts receivable are generated by one customer. (2) BASIS OF PRESENTATION The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") for interim financial information and with the instructions to Form 10-Q. Accordingly, they do not include all of the information and footnote disclosures required to be presented for complete financial statements. In the opinion of management, these consolidated financial statements contain all adjustments (consisting of normal recurring adjustments) considered necessary for fair presentation. The results of operations for the three m

Notes to Consolidated Financial Statements

Notes to Consolidated Financial Statements Impairment of Long-Lived Assets – The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. To determine recoverability of a long-lived asset, management evaluates whether the estimated future undiscounted net cash flows from the asset are less than its carrying amount. If impairment is indicated, the long-lived asset would be written down to fair value. Fair value is determined by an evaluation of available price information at which assets could be bought or sold, including quoted market prices, if available, or the present value of the estimated future cash flows based on reasonable and supportable assumptions. Leases - At lease inception, the Company determines whether an arrangement is or contains a lease. Operating leases are included in ope

View Full Filing

View this 10-Q filing on SEC EDGAR